$AMPE I’m very very surprised that after all the investor calls and PR’s this ended with “we are discontinuing the development of Ampion”. I understand the new CEO hasn’t been apart of the misinformation from the previous team. But it does seem odd he wasn’t educated enough on the product and results of the trials until a year and half after he was hired. What a shame. I could potentially understand running another trial but to completely discontinue the drug is pretty severe. If it was that ineffective how is just realizing this now?